Skip to main content
OpenTrials
Completed

NCT Number: NCT00152477

A Study of Paclitaxel/Carboplatin With or Without CDP791 in Patients With Lung Cancer

A 2-part study to examine safety, tolerability and pharmacokinetics (part 1), and anti-tumour effects (part 2), of CDP791 combined with carboplatin and paclitaxel.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Carcinoma Bronchial Neoplasms Carcinoma, Bronchogenic Carcinoma, Non-Small-Cell Lung Lung Diseases Lung Neoplasms Neoplasms Neoplasms by Histologic Type Neoplasms by Site Neoplasms, Glandular and Epithelial Non-squamous Non-small-cell Lung Cancer Respiratory Tract Diseases Respiratory Tract Neoplasms Thoracic Neoplasms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Budapest, Hungary

Loading trial locations.

About this study

This is a two part study to investigate the safety and anti-tumour effects of standard chemotherapy, plus an investigational drug (CDP791), in patients with advanced non small cell lung cancer.

In part one, patients receive carboplatin and paclitaxel chemotherapy together with one of 2 doses of CDP791. The main aim of this part is to investigate safety and tolerability of carboplatin/paclitaxel plus CDP791.

If part one confirms that the combination of drugs is safe and well tolerated, 156 patients will enter part 2. They will be randomized to receive either carboplatin/paclitaxel (C/P) alone, or C/P plus one of 2 doses of CDP791. The main aim of this part of the study is to compare the anti-tumor effects of CDP791 plus C/T with those of C/T alone. Participants will receive up to six cycles of chemotherapy with or without CDP791. Those whose disease stabilizes, or responds, will be eligible to continue to receive CDP791. Participants in the C/T alone arm whose disease progresses will be eligible to receive CDP791 monotherapy.

Participants will be followed up longterm, so that survival can be measured.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Inclusion criteria

  • Male and female subjects with Stage IIIb (with malignant pleural effusion or if no pleural effusion is present subjects who are not candidates for combined modality therapy), Stage IV, or recurrent non-squamous, non-small-cell lung carcinoma.
  • The subject must be aged 18 years or above.
  • The subject must have ECOG performance status of 0 or 1 and a life expectancy of at least three months.
  • Subjects will have measurable disease.
  • The subject must be able to understand the information provided to them and to give written informed consent.
  • Female subjects must be either postmenopausal, surgically sterilized, or using a method of contraception judged reliable by the Investigator.
  • Male subjects must be using a method of contraception judged reliable by the Investigator.

Exclusion criteria

  • Subjects with squamous cell lung carcinoma.
  • Subjects with lung lesions located centrally in the chest that involve major blood vessels.
  • Concurrent active malignancy other than nonmelanoma skin cancer or carcinoma in situ of the cervix. Subjects with previous malignancies are eligible provided that they have been disease free for five years or more.
  • Presence of additional major chronic disease such as hepatic or renal dysfunction, cardiac dysfunction, peripheral vascular disease, evidence of a myocardial infarction within six months of Screening visit, tuberculosis or epilepsy.
  • Subjects known to be infected with hepatitis B or C virus or HIV 1 or 2.
  • Any evidence of serious active infection (ie requiring an iv antibiotic or antiviral agent).

Exclusion criteria

Treatment and study plan

carboplatin

Drug

10mg/mL vial AUC6. Dosed intravenously over 15-30 minutes immediately following paclitaxel, Day 0 of each cycle.

Each cycle to be repeated every three weeks for a maximum of six cycles.

Other names: CBDCA, Paraplatin, JM-8, NSC 241240

paclitaxel

Drug

6mg/mL vial 200 mg/m2 iv over three hours, Day 0. Each cycle to be repeated every 3 weeks for a maximum of 6 cycles.

Other names: Taxol, NSC #673089

CDP791 10mg/kg

Drug

CDP791 20mg/mL vial CDP791 diluted (10mg/kg or 20mg/kg) in 0.9% saline will be given as a 200mL iv infusion over approximately 60 minutes following administration of standard chemotherapy.

CDP791 20mg/kg

Drug

CDP791 20mg/kg CDP791 diluted (10mg/kg or 20mg/kg) in 0.9% saline will be given as a 200mL iv infusion over approximately 60 minutes following administration of standard chemotherapy.

Primary outcomes

  1. Tumor Response Rate (RR)

    Time frame: 24 weeks

    Participants are evaluated for response using Response Evaluation Criteria in Solid Tumors (RECIST) (Therasse P et al; 2000). The tumor response rate is calculated as the total number of subjects whose best overall response is a complete response (CR)= disappearance of all target lesions; or a partial response (PR) = >=30 % decrease in the sum of the longest diameter of target lesions, divided by the number of randomized subjects (RS):

    (CR + PR) / RS.

Secondary outcomes

  1. Progression Free Survival (PFS)

    Time frame: Up to 57 weeks

    Progression free survival (PFS) is defined as time from date of randomization until the date progressive disease (PD) is first recorded or until death, whichever is first.

  2. Time to Treatment Failure

    Time frame: Up to 57 weeks

    Time to treatment failure (TTF) is defined as the time from date of randomization until the date of progression, death or, for subjects who discontinued treatment for toxicity reason, their last dosing date, whichever occurs first.

  3. Overall Survival

    Time frame: Up to 57 weeks

    Overall survival is defined as the time from date of randomization until the date of death.

  4. Duration of Overall Response

    Time frame: Up to 57 weeks

    The duration of overall response is measured from the time measurement criteria are first met for complete response (CR) or partial response (PR), whichever is recorded first, until the first date of documented progressive disease or death.

  5. Time to Response

    Time frame: Week 24

    Time to response is defined as the time from the first dose of study therapy until measurement criteria are first met for complete response or partial response (whichever is recorded first).

Sponsors and collaborators

Lead sponsor

UCB Pharma

Industry

Registry information

Official study title

A Two-Part, Open Label Phase II Trial: Part One, Dose Escalation Safety; Part Two, Randomized/Comparing CDP791 Plus Carboplatin/Paclitaxel With Carboplatin/Paclitaxel Alone in Subjects With Locally Advanced or Metastatic Non-Squamous Non-Small-Cell Lung Cancer

Important dates

Study start
2005
Primary completion
2009
Study completion
2009
First posted
Sep 9, 2005
Registry last updated
Apr 12, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.